demonstrated that based on syngeneic lung cancer mouse model, low-dose apatinib could result in alleviating hypoxia, increasing infiltration of CD8+ T cells, reducing recruitment of TAMs in tumor and decreasing TGF-β level both in tumor and serum (49). This evidence concerns the gene CD8A and lung carcinoma.